Similar articles

Abstract: To compare the continuous infusion and intermittent bolus injection administration protocols of doxorubicin (Dox) under the same cumulative dose (12 mg/kg), and establish a rat dilated cardiomyopathy model with improved survival, a total of 150 Sprague-Dawley (SD) rats were divided into three groups: a control group, administered with normal saline; a Dox 1 group, administration twice a week at 1 mg/kg; a Dox 2, administration once a week at 2 mg/kg. Mortality rates in the Dox 1 and Dox 2 groups were 22% and 48%, respectively (P<0.05). As shown by echocardiography, both Dox groups exhibited significant chamber dilatation and reduced cardiac function (all P<0.05 vs. control). Plasma brain natriuretic peptide and C-reactive protein concentrations were significantly increased (P<0.05) with both Dox regimens. The concentrations of Caspase-3 in myocardial tissues of rats significantly increased in both doxorubicin regimens. Myocardial metabolism imaging by histology and ¹⁸F-fluoro-deoxyglucose-positron emission tomography (¹⁸FDG-PET) both revealed decreased myocardial viability and necrosis, and even interstitial fibrosis, in left ventricles (LVs) in both Dox groups. Serum creatinine and aspartate aminotransferase concentrations were significantly higher in the Dox 2 model than in the Dox 1 model. doxorubicin given at both regimens induced dilated cardiomyopathy, while its administration at lower doses with more frequent infusions reduced the mortality rate.

提高扩张型心肌病动物模型的生存率

[1]Baba, S., Heike, T., Yoshimoto, M., et al., 2007. Flk1⁺ cardiac stem/progenitor cells derived from embryonic stem cells improve cardiac function in a dilated cardiomyopathy mouse model. Cardiovasc. Res., 76(1):119-131.

[2]Bardi, E., Bobok, I., Olah, A.V., et al., 2007. Anthracycline antibiotics induce acute renal tubular toxicity in children with cancer. Pathol. Oncol. Res., 13(3):249-253.

[3]Brunner, S., Todica, A., Boning, G., et al., 2012. Left ventricular functional assessment in murine models of ischemic and dilated cardiomyopathy using [¹⁸F]FDG-PET: comparison with cardiac MRI and monitoring erythropoietin therapy. EJNMMI Res., 2(1):43.

[4]Carvalho, C., Santos, R.X., Cardoso, S., et al., 2009. Doxorubicin: the good, the bad and the ugly effect. Curr. Med. Chem., 16(25):3267-3285.

[5]Cryns, V., Yuan, J., 1998. Proteases to die for. Genes Dev., 12(11):1551-1570.

[6]Delgado-Roche, L., Hernandez-Matos, Y., Medina, E.A., et al., 2014. Ozone-oxidative preconditioning prevents doxorubicin-induced cardiotoxicity in Sprague-Dawley Rats. Sultan Qaboos Univ. Med. J., 14(3):e342-e348.

[7]Deng, S., Kruger, A., Schmidt, A., et al., 2009. Differential roles of nitric oxide synthase isozymes in cardiotoxicity and mortality following chronic doxorubicin treatment in mice. Naunyn-Schmiedeberg’s Arch. Pharmacol., 380(1):25-34.

[8]El-Sayyad, H.I., Ismail, M.F., Shalaby, F.M., et al., 2009. Histopathological effects of cisplatin, doxorubicin and 5-flurouracil (5-FU) on the liver of male albino rats. Int. J. Biol. Sci., 5(5):466-473.

[9]Faleiro, L., Kobayashi, R., Fearnhead, H., et al., 1997. Multiple species of CPP32 and MCh2 are the major active Caspases present in apoptotic cells. EMBO, 16(9):2271-2281.

[10]Gava, F.N., Zacche, E., Ortiz, E.M., et al., 2013. Doxorubicin induced dilated cardiomyopathy in a rabbit model: an update. Res. Vet. Sci., 94(1):115-121.

[11]Gu, R., Bai, J., Ling, L., et al., 2012. Increased expression of integrin-linked kinase improves cardiac function and decreases mortality in dilated cardiomyopathy model of rats. PLoS ONE, 7(2):e31279.

[12]Haider, N., Narula, J., Hajjar, R.J., et al., 1995. Apoptosis in human explanted cardiomyopathic hearts suggests programmed progression of dilatedcardiomyopathy. Circulation, 92(8):3479-3479.

[13]Handa, N., Magata, Y., Mukai, T., et al., 2007. Quantitative FDG-uptake by positron emission tomography in progressive hypertrophy of rat hearts in vivo. Ann. Nucl. Med., 21(10):569-576.

[14]Hayward, R., Hydock, D.S., 2007. Doxorubicin cardiotoxicity in the rat: an in vivo characterization. J. Am. Assoc. Lab. Anim. Sci., 46(4):20-32.

[15]Ishida, M., Tomita, S., Nakatani, T., et al., 2004. Bone marrow mononuclear cell transplantation had beneficial effects on doxorubicin-induced cardiomyopathy. J. Heart Lung Transplant., 23(4):436-445.

[16]Iwata, Y., Ohtake, H., Suzuki, O., et al., 2013. Blockade of sarcolemmal TRPV2 accumulation inhibits progression of dilated cardiomyopathy. Cardiovasc. Res., 99(4):760-768.

[17]Jones, R.L., Swanton, C., Ewer, M.S., 2006. Anthracycline cardiotoxicity. Expert Opin. Drug Saf., 5(6):791-809.

[18]Kalender, Y., Yel, M., Kalender, S., 2005. Doxorubicin hepatotoxicity and hepatic free radical metabolism in rats. The effects of vitamin E and catechin. Toxicology, 209(1):39-45.

[19]Kawano, H., Okada, R., Kawano, Y., et al., 1994. Apoptosis in acute and chronic myocarditis. Jpn. Heart, 35(6):745-750.

[20]Leontyev, S., Schlegel, F., Spath, C., et al., 2013. Transplantation of engineered heart tissue as a biological cardiac assist device for treatment of dilated cardiomyopathy. Eur. J. Heart Fail., 15(1):23-35.

[21]Liu, H.Z., Gao, C.Y., Wang, X.Q., et al., 2012. Angiotensin(1-7) attenuates left ventricular dysfunction and myocardial apoptosis on rat model of adriamycin-induced dilated cardiomyopathy. Chin. J. Cardiol., 40(3):219-224 (in Chinese).

[22]Lou, H., Danelisen, I., Singal, P.K., 2005. Involvement of mitogen-activated protein kinases in adriamycin-induced cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol., 288(4):H1925-H1930.

[23]Lu, L., Wu, W., Yan, J., et al., 2009. Adriamycin-induced autophagic cardiomyocyte death plays a pathogenic role in a rat model of heart failure. Int. J. Cardiol., 134(1):82-90.

[24]Mamamtavrishvili, N.D., Kvirkveliia, A.A., Abashidze, R.I., et al., 2008. Role of immune inflammatory activity in chronic heart failure progress. Georgian Med. News, 160/161:30-34.

[25]Martins, L.M., Kottke, T., Mesner, P.W., et al., 1997. Activation of multiple interleukin 1 β-bconverting enzyme homologues in cytosol and nuclei of HL-60 cells during etoposideinduced apoptosis. J. Biol. Chem., 272(11):7421-7430.

[26]Nicholson, D.W., Thornberry, A., 1997. Caspase: killer proteases. Trends Biochem. Sci., 22(8):299-306.

[27]Octavia, Y., Tocchetti, C.G., Gabrielson, K.L., et al., 2012. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J. Mol. Cell. Cardiol., 52(6):1213-1225.

[28]Plana, J.C., Galderisi, M., Barac, A., et al., 2014. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur. Heart J. Cardiovasc. Imaging, 15(10):1063-1093.

[29]Polverino, A.J., Patterson, S.D., 1997. Selective activation of caspases during apoptotic induction in HL-60 cells. J. Biol. Chem., 272(11):7013-7021.

[30]Satoh, M., Nakmura, M., Akatsu, T., et al., 2005. C-reactive protein co-expresses with tumor necrosis factor-α in the myocardium in human dilated cardiomyopathy. Eur. J. Heart Fail., 7(5):748-754.

[31]Stegger, L., Schafers, K.P., Flogel, U., et al., 2005. Monitoring left ventricular dilation in mice with PET. J. Nucl. Med., 46(9):1516-1521.

[32]Thornberry, N.A., Lazebnik, Y., 1998. Caspase: enemies within. Science, 281(5381):1312-1316.

[33]Turakhia, S., Venkatakrishnan, C.D., Dunsmore, K., et al., 2007. Doxorubicin-induced cardiotoxicity: direct correlation of cardiac fibroblast and H9c2 cell survival and aconitase activity with heat shock protein 27. Am. J. Physiol. Heart Circ. Physiol., 293(5):H3111-H3121.

[34]Vejpongsa, P., Yeh, E.T., 2014. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J. Am. Coll. Cardiol., 64(9):938-945.

[35]Yu, S.Y., Liu, L., Li, P., et al., 2013. Rapamycin inhibits the mTOR/p70S6K pathway and attenuates cardiac fibrosis in adriamycin-induced dilated cardiomyopathy. Thorac. Cardiovasc. Surg., 61(3):223-228.

[36]Zimmermann, O., Bienek-Ziolkowski, M., Wolf, B., et al., 2009. Myocardial inflammation and non-ischaemic heart failure: is there a role for C-reactive protein? Basic Res. Cardiol., 104(5):591-599.

[37]List of electronic supplementary materials

[38]Fig. S1 Myocardial metabolism imaging by ¹⁸FDG-PET/CT